ACXP earnings: next report 2026-08-14, real EPS beat/miss history, analyst consensus Buy, P/E -0.30. Updated 2026-07-23.
Acurx Pharmaceuticals (ACXP) Research Hub
Acurx Pharmaceuticals (ACXP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.4 USD (-0.71%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.30, market cap 0.00B. This hub links to the full technical, earnings and options research available for ACXP.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.4 USD (-0.71%) |
| 52-week range | 1.35 USD – 1.88 USD |
| Trend regime | Range |
| 14-day RSI | 39.7 (Bearish) |
| Trailing P/E | -0.30 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-14 |
Available research for ACXP
Covered Call on ACXP: how it works, illustrative setup around the real 1.4 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ACXP: how it works, illustrative setup around the real 1.4 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ACXP: how it works, illustrative setup around the real 1.4 USD price, max profit/loss, breakeven and when to use it. Educational.
ACXP technical analysis: range, last 1.4 USD, RSI 39.7, 52w range 1.35 USD–1.88 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ACXP in?
Acurx Pharmaceuticals (ACXP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ACXP in an uptrend or downtrend?
As of 2026-09-11, ACXP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ACXP's trailing P/E ratio?
ACXP's trailing P/E is -0.30, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does ACXP next report earnings?
ACXP is next scheduled to report earnings on 2026-08-14, with a consensus EPS estimate of -0.42 USD.